Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that human epidermal stem cells can adapt to small temperature variations via mTOR signaling, and that prolonged mTORC1 inhibition supports stem cell maintenance.

5% ET-02 is a more effective and safe treatment for hair loss than current options.

CaBP1 and 2 are important for maintaining the activity of calcium channels necessary for hearing in inner ear cells.

In this study, patients with alopecia areata who experienced sustained hair regrowth while being treated with baricitinib showed improvements in health-related quality of life and reductions in anxiety and depression symptoms over 104 weeks, according to the BRAVE-AA phase III trials.

TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.

This study found that retinol palmitate treatment in patients with stage Ia non-small-cell lung cancer may reduce cancer relapses, but longer follow-up is needed to confirm its efficacy.

This study describes characteristics and outcomes for adults initiating ritlecitinib for severe alopecia areata, highlighting increased hair regrowth and physician satisfaction with longer treatment durations, despite ongoing psychosocial impacts like embarrassment and anxiety among patients.

In this prospective, placebo-controlled study, the researchers observed a significant reduction in hair shedding in women after applying the combined topical treatment DA-OTC-002, containing synephrine and TAAR agonists, compared to placebo, showing a 62.5% average reduction with no reported adverse events.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This source reports that the approval of baricitinib and ritlecitinib, which are JAK inhibitors, has marked a significant advancement in treating severe alopecia areata (AA), and suggests that additional treatments with new mechanisms may further improve patient outcomes in the future.

The study found that women with hyperandrogenic PCOS have higher levels of AKT1 and AKT2 proteins in their cells, which may lead to cell dysfunction.

The researchers reported that baricitinib treatment for at least 52 weeks reduced severe alopecia areata severity and improved psychological well-being and quality of life in study participants.

This study highlights the recent FDA approval of baricitinib as the first on-label treatment for severe alopecia areata, whereas previous treatments were off-label therapies like systemic steroids and immunosuppressants.

Activin A and Follistatin affect how mouse hair follicles grow.

In this study, all-trans retinoic acid was found to protect against oxidative stress-induced apoptosis in cultured hair cell-like cells.

This review discusses the role of Ysc84/SH3yl1 proteins in linking actin regulation to membrane morphology changes but reports no new experimental results.

In this study, researchers found that among adults with severe alopecia, continued treatment with baricitinib for 104 weeks maintained hair regrowth effectively in those who responded at 52 weeks, with improved outcomes noted in some initially non-responders receiving 4 mg.

This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.

This study found that combining carboxytherapy with standard treatment for androgenetic alopecia in men significantly improved clinical outcomes and patient satisfaction compared to standard treatment alone over a 24-week period.

In this study, rhKGF2 significantly promoted hair regeneration and enhanced the formation and maturation of hair follicles in experimental bald rats, suggesting potential clinical application.

The document discusses a special exam case for formulating and using systemic therapy named Athena.

This study found that the oral JAK inhibitors ritlecitinib and brepocitinib were effective in maintaining hair regrowth in alopecia areata with continuous use, though efficacy decreased after withdrawal.

This study found that the L457(3.43)R mutation in the human luteinizing hormone receptor increases phosphodiesterase activity, reducing hormonal response despite elevated basal cAMP levels.

In this real-world study, aumolertinib was found to improve patient-reported outcomes and maintain high disease control and objective response rates similar to those reported in the AENEAS trial for advanced NSCLC patients, supporting its use in first-line treatment.

Baricitinib is generally safe for long-term use in treating severe alopecia areata.

This review outlines advances in topical PROTACs for localized protein degradation, focusing on AH-001 and GT20029 for skin conditions, but presents no new clinical trial results.

This study found that FZD2 is crucial for hair follicle formation and postnatal growth in mice and has a novel role in regulating early epidermal development, including stratification and cornification.

This study found that deleting Stim1 and Stim2 in mature T regulatory cells disrupts Ca 2+ signaling, preventing their differentiation and leading to severe autoimmune disorders in mice.